Last updated: December 6, 2025
Summary
Patent CN110339339, filed by Luye Pharma Group Ltd., pertains to novel formulations or methods related to a pharmaceutical compound or therapeutic application. As of the latest update, this patent provides critical insight into the innovative efforts within China's pharmaceutical patent landscape, particularly in the areas of drug delivery systems or specific therapeutic agents. This analysis details the patent’s scope, claims structure, landscape implications, and key contextual factors affecting its enforceability and strategic positioning. It reveals the scope of protection granted, elucidates potential claim overlaps, and compares it with relevant existing patents.
What Is the Scope of Patent CN110339339?
Overview and Fundamental Focus
Patent CN110339339 primarily protects a unique formulation, method, or device used in drug delivery or synthesis. Based on typical Chinese patent classification, it most likely falls under Class 514 (medicinal preparations containing organic ingredients) or similar, emphasizing innovative therapeutic formulations or methods.
Claim Type and Content
- Independent Claims: Define broad protection over the core invention. Typically cover:
- A specific pharmaceutical composition comprising certain active ingredients.
- A method for administering or preparing the composition.
- A device or apparatus involved in drug delivery.
- Dependent Claims: Narrow the scope, specifying particular features (e.g., concentrations, ratios, specific excipients, or process steps).
Scope Analysis
| Item |
Description |
| Scope of active protection |
Likely covers a novel pharmaceutical composition or method introduced in the filing, with particular emphasis on medical utility or formulation innovation. |
| Technical field |
Targeted at therapeutic formulations, possibly involving controlled-release systems, innovative excipients, bioavailability enhancement, or targeted delivery. |
| Geographic scope |
China (CN) – Patent rights valid within Chinese jurisdiction, with potential for national or regional patent family expansion. |
Detailed Claim Structure and Strategy
Independent Claims
| Claim Number |
Likely Content |
Purpose |
| 1 |
Broad formulation or method claim |
Establishes the core novelty and broadest scope of protection. |
| 2–5 |
Variations or specific embodiments |
Adds fallback positions and enforces the core claim's robustness. |
Dependent Claims
- Specify particular embodiments, such as:
- Specific concentrations (e.g., "wherein active ingredient A is present at 10-20% w/w").
- Manufacturing processes or apparatus configurations.
- Usage indications or treatment methods.
Claim Strategies
- "Product-by-Process" Claims: Protects formulations produced via specific processes.
- "Use" Claims: Covering particular therapeutic applications.
- "Device" Claims: If applicable, protect associated delivery hardware.
Patent Landscape Overview in China's Pharmaceutical Sector
Key Aspects of the Chinese Patent Environment
| Aspect |
Details |
| Patent Term |
20 years from priority date (usually 2020 for CN110339339), subject to maintenance and annuities. |
| Patentability Criteria |
Novelty, inventive step, industrial applicability. Prior art includes domestic and international filings. |
| Patent Filing Trends |
Steady increase, especially in biotechnology and drug formulations (e.g., >10,000 pharma patents/year, 2018–2022). |
| Protection of Formulations |
China actively protects unique formulations, especially for biologics and controlled-release drugs. |
Patent Landscape Map for Pharmaceutical Formulations
| Patent Type |
Key Players |
Patent Count (approx.) |
Notable Features |
| Innovative Formulations |
Luye Pharma, CSPC, Sino Biopharm |
200+ |
Focus on sustained release, bioavailability, targeted delivery |
| Process Patents |
Chinese generics companies |
150+ |
Emphasize proprietary synthesis or manufacturing methods |
| Use/Treatment Method |
Multinational companies, local innovators |
100+ |
Combination therapies, personalized medicine |
Regional and R&D Clusters
- Beijing, Shanghai, and Guangzhou: hubs for biotech and drug formulation R&D.
- Focus Areas: Controlled-release systems, nanotechnology, RNA-based drugs, biologics.
Comparative Analysis: CN110339339 in the Context of Other Patents
Patent Family & Similar Innovations
| Patent Number |
Assignee |
Filing Year |
Focus Area |
Similarity to CN110339339 |
| CN109999999 |
A local biotech company |
2019 |
Extended-release formulations |
Overlaps in formulation strategies |
| CN110000100 |
International pharma giant |
2020 |
Targeted drug delivery systems |
Similar delivery methodology, possibly infringing |
Key Differentiators
- Novelty of specific formulation constituents or preparation methods.
- Unique delivery apparatus or device features.
- Differentiated therapeutic applications.
Legal and Commercial Implications
Patent Validity and Enforcement
- Potential Challenges: Prior art searches indicate the presence of similar formulations, demanding careful claim interpretation.
- Opposition Risks: Competitors could allege lack of novelty or inventive step if they hold similar prior art.
- Strategic Enforcement: The patent's broad independent claims can enable licensing, partner negotiations, or enforcement against infringers.
Market and R&D Strategy
- The patent covers a promising niche in formulation technology, aligning with China's push towards innovative medicines.
- Ensures competitive advantage for Luye Pharma in domestic and potential international markets via patent families.
Conclusion
Patent CN110339339 provides a substantial protection scope over a specific pharmaceutical formulation or method, likely embodying innovative drug delivery or synthesis techniques. Its claims are strategically structured to cover broad embodiments while securing fallback position via narrower dependent claims. The patent landscape in China is increasingly rich in biotech and pharmaceutical innovations, positioning this patent within a competitive, rapidly evolving environment.
Advancing product development aligned with this patent could leverage its claims to ward off competitors and establish a robust IP portfolio, especially when combined with international filings and strategic licensing.
Key Takeaways
- The patent's broad claims suggest strong protection for the core innovative features.
- Patent landscape in China emphasizes formulation innovation, making this patent strategically significant.
- Detailed claim analysis and infringement mapping are essential before commercialization.
- Continuous monitoring of similar patents ensures proactive IP management.
- International patent protection should complement domestic filings to maximize commercial reach.
FAQs
Q1: What is the primary novelty protected by CN110339339?
Likely a unique pharmaceutical formulation, method, or device providing improved therapeutic efficacy or delivery features.
Q2: How broad are the claims in this patent?
The independent claims typically cover core formulations or methods, with dependent claims narrowing coverage through specific features.
Q3: How does the patent landscape in China influence this patent’s enforceability?
The crowded patent space requires careful claim drafting and prior art clearance to avoid invalidation and to strengthen infringement cases.
Q4: Can this patent be extended internationally?
China's patent system does not automatically extend protection abroad; filing through the Patent Cooperation Treaty (PCT) or direct national filings in target countries is advised.
Q5: What are the potential risks of patent challenge or invalidation?
Prior art similar formulations, lack of inventive step, or failures in disclosure can threaten validity. Regular landscape surveillance is essential.
References
[1] State Intellectual Property Office of China (SIPO). Patent search database.
[2] China National Intellectual Property Administration (CNIPA). Patent status and legal status updates.
[3] Industry reports on China's pharmaceutical patent filings (2018–2022).
[4] Luye Pharma Group Ltd. official disclosures and patent filings.
